AMP as a Better Delivery System of Adenosine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00179010
Recruitment Status : Suspended (In process of renewing IND for AMP)
First Posted : September 15, 2005
Last Update Posted : February 4, 2015
Information provided by (Responsible Party):
Italo Biaggioni, Vanderbilt University

September 13, 2005
September 15, 2005
February 4, 2015
October 2003
January 2017   (Final data collection date for primary outcome measure)
  • Interstitial adenosine levels [ Time Frame: Duration of ia infusion ]
  • Forearm blood flow [ Time Frame: Duration of ia infusion ]
  • Interstitial adenosine levels
  • Forearm blood flow
  • Heart rate
  • Blood pressure
Complete list of historical versions of study NCT00179010 on Archive Site
Not Provided
Not Provided
Not Provided
AMP as a Better Delivery System of Adenosine
Use of AMP to Improve Tissue Delivery of Adenosine
Adenosine and AMP are substances normally present in the body. Adenosine is also given for the treatment of some heart rhythm problems and may be used to reduce heart damage during heart attacks. The problem in using adenosine is that it is taken up by cells and, therefore, very little of the adenosine we give by vein or in the artery actually reaches the tissue. We propose to use AMP as a way to improve delivery of adenosine. AMP is inactive by itself, but is converted to adenosine in tissue. We hope that by giving AMP we will increase levels of adenosine in tissue. To see if this is true, we will give either adenosine or AMP into the forearm artery while we measure how much adenosine reaches the forearm tissue.
Not Provided
Not Applicable
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
  • Drug: Adenosine
    Adenosine intrarterial (intrabrachial) infusion at 3 diferent doses for 15 minutes each
  • Drug: Adenosine Mono Phosphate (AMP)
    Intraterial infusion of AMP at 3 different doses for 15 minutes each (at equimolar doses as adenosine)
  • Experimental: 1
    Intrarterial infusion of adenosine
    Intervention: Drug: Adenosine
  • Experimental: 2
    Intrarterial infusion of AMP
    Intervention: Drug: Adenosine Mono Phosphate (AMP)
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
January 2017
January 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy volunteers
  • Age 18-65
  • Non smokers

Exclusion Criteria:

  • Smokers
  • Any chronic disease
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Italo Biaggioni, Vanderbilt University
Vanderbilt University
Not Provided
Principal Investigator: Italo Biaggioni, M.D. Vanderbilt University
Vanderbilt University
February 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP